ASCO GI 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASCO GI 2022 Conference Coverage

Videos

Playback speed

10 seconds

ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis in CheckMate 649: Nivo + Chemo vs. Chemo as 1L Treatment for Advanced GC/GEJC/EAC

By ASCO GI 2022 Conference Coverage FEATURING Ryan Sugarman

433 views

February 3, 2022

0 Comments

Videos

ASCO GI 2022 Biliary Cancer Updates

ASCO GI 2022 Conference Coverage

K. Spencer

57 views

ASCO GI 2022 Updates in HCC

ASCO GI 2022 Conference Coverage

S. Sadeghi

97 views

ASCO GI 2022 Pembro +/- Chemo vs. Chemo Alone for PD-L1+ Advanced GC…

ASCO GI 2022 Conference Coverage

Z. Wainberg

516 views

ASCO GI 2022 on the Emerging Roles of ctDNA as a Tool in Metastatic …

ASCO GI 2022 Conference Coverage

A. Dasari

242 views

ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity…

ASCO GI 2022 Conference Coverage

R. Sugarman

433 views

ASCO GI 2022 CRC Cases: Is It Time to De-Intensify Oxaliplatin to Im…

ASCO GI 2022 Conference Coverage

G. A. Brooks

265 views

ASCO GI 2022 Results From the PREVAIL ctDNA Study: Liquid Biopsy for…

ASCO GI 2022 Conference Coverage

J. Mencel

143 views

ASCO GI 2022 Highlights on a Multicenter Phase II Study of Neoadjuva…

ASCO GI 2022 Conference Coverage

R. Kelly

135 views

13:50

ASCO GI 2022 Conference Coverage

[PRIVATE - new ASCO version uploaded] ASCO GI 2022 Updates on the En…

Feat. V. Morris

ASCO GI 2022 Review of the Emerging Roles of ctDNA as a Tool for Ear…

ASCO GI 2022 Conference Coverage

N. Starling

370 views

ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Study o…

ASCO GI 2022 Conference Coverage

Y. Y. Janjigian

230 views

ASCO GI 2022 Phase I/II Study of Regorafenib and Pembrolizumab in Re…

ASCO GI 2022 Conference Coverage

A. Barzi

233 views

ASCO GI 2022 on Chemo and CRT Neoadjuvant Regimens for Locally Advan…

ASCO GI 2022 Conference Coverage

K. Kato

204 views

ASCO GI 2022 Updates on Integrating New Targeted Therapy Into Locore…

ASCO GI 2022 Conference Coverage

F. Rocha

386 views

ASCO GI 2022 on mFOLFOX6/Bev +/- Nivo for 1L Treatment of mCRC: Phas…

ASCO GI 2022 Conference Coverage

H. Lenz

489 views

ASCO GI 2022 on Triplet vs. Doublet Systemic Therapy for Advanced Re…

ASCO GI 2022 Conference Coverage

H. K. Sanoff

323 views

ASCO GI 2022 Updates on FOLFOX + nab-Paclitaxel (FOLFOX-A) in the Tr…

ASCO GI 2022 Conference Coverage

A. Benson

438 views

ASCO GI 2022 Updates on IO for Early Stage HCC

ASCO GI 2022 Conference Coverage

A. Villanueva

172 views

ASCO GI 2022 Long-Term Follow-Up of the GERCOR NIPICOL Study: One-Ye…

ASCO GI 2022 Conference Coverage

R. Cohen

440 views

ASCO GI 2022 Update on NIVO+ Chemo vs Chemo as 1L Treatment for Adva…

ASCO GI 2022 Conference Coverage

K. Shitara

427 views

ASCO GI 2022 Updates on IMbrave150 Trial: Exploratory Efficacy & Saf…

ASCO GI 2022 Conference Coverage

H. Chong Toh

93 views

ASCO GI 2022 Highlights: Host-Related Biomarkers Including Gut Micro…

ASCO GI 2022 Conference Coverage

Y. Sunakawa

191 views

ASCO GI 2022 Highlights: Clinical Utility of MSI-H Identified on Liq…

ASCO GI 2022 Conference Coverage

P. Kasi

365 views